Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 7 (2010), Issue 10 (October)

  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    Lancet, 376(9747): 1147-54. [Abstract] [Full-text]
  2. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort.
    Jpn J Clin Oncol, 40(10): 973-9. [Abstract] [Full-text]
  3. Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.
    Jpn J Clin Oncol, 40(10): 967-72. [Abstract] [Full-text]
  4. Balancing the harms and benefits of early detection of prostate cancer.
    Cancer, 116(20): 4857-65. [Abstract] [Full-text]
  5. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.
    Cancer, 116(20): 4711-7. [Abstract] [Full-text]
  6. Underuse of colorectal cancer screening among men screened for prostate cancer: a teachable moment?
    Cancer, 116(20): 4703-10. [Abstract] [Full-text]
  7. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer.
    Cancer Invest, 28(9): 917-24. [Abstract] [Full-text]
  8. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    J Urol, 184(5): 1971-6. [Abstract] [Full-text]
  9. Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy.
    J Urol, 184(5): 1963-9. [Abstract] [Full-text]
  10. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression.
    J Urol, 184(5): 2172-8. [Abstract] [Full-text]
  11. Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy.
    J Urol, 184(5): 1977-81. [Abstract] [Full-text]
  12. Microvesicle induction of prostate specific gene expression in normal human bone marrow cells.
    J Urol, 184(5): 2165-71. [Abstract] [Full-text]
  13. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
    J Urol, 184(5): 1947-52. [Abstract] [Full-text]
  14. Disproportionate presentation of high risk prostate cancer in a safety net health system.
    J Urol, 184(5): 1931-6. [Abstract] [Full-text]
  15. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
    J Urol, 184(5): 1958-62. [Abstract] [Full-text]
  16. Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test.
    J Urol, 184(5): 1937-41. [Abstract] [Full-text]
  17. Initial atypical diagnosis with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy.
    J Urol, 184(5): 1953-7. [Abstract] [Full-text]
  18. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
    J Urol, 184(5): 1942-6. [Abstract] [Full-text]
  19. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
    Clin Chim Acta, 411(23): 1935-9. [Abstract] [Full-text]
  20. Nanoparticle-induced vascular blockade in human prostate cancer.
    Blood, 116(15): 2847-56. [Abstract] [Full-text]
  21. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death.
    Cancer Lett, 299(1): 54-62. [Abstract] [Full-text]
  22. Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
    Cancer Lett, 299(1): 45-53. [Abstract] [Full-text]
  23. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
    Cancer Lett, 299(1): 11-21. [Abstract] [Full-text]
  24. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death.
    Cancer Lett, 299(1): 54-62. [Abstract] [Full-text]
  25. Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
    Cancer Lett, 299(1): 45-53. [Abstract] [Full-text]
  26. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
    Cancer Lett, 299(1): 11-21. [Abstract] [Full-text]
  27. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death.
    Cancer Lett, 299(1): 54-62. [Abstract] [Full-text]
  28. Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
    Cancer Lett, 299(1): 45-53. [Abstract] [Full-text]
  29. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
    Cancer Lett, 299(1): 11-21. [Abstract] [Full-text]
  30. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
    J Clin Oncol, 28(30): 4562-7. [Abstract] [Full-text]
  31. Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions.
    J Infect Dis, 202(10): 1470-7. [Abstract] [Full-text]
  32. Expression of follicle-stimulating hormone receptor in tumor blood vessels.
    N Engl J Med, 363(17): 1621-30. [Abstract] [Full-text]
  33. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
    Endocrinology, 151(11): 5136-45. [Abstract] [Full-text]
  34. Fish consumption and prostate cancer risk: a review and meta-analysis.
    Am J Clin Nutr, 92(5): 1223-33. [Abstract] [Full-text]
  35. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines.
    Cell Biol Toxicol, 26(6): 553-67. [Abstract] [Full-text]
  36. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines.
    Cell Biol Toxicol, 26(6): 553-67. [Abstract] [Full-text]
  37. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
    Int J Radiat Oncol Biol Phys, 78(4): 1210-8. [Abstract] [Full-text]
  38. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1104-10. [Abstract] [Full-text]
  39. ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells.
    J Biol Chem, 285(44): 33940-8. [Abstract] [Full-text]
  40. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation.
    Exp Cell Res, 316(19): 3207-26. [Abstract] [Full-text]
  41. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.
    Int J Radiat Oncol Biol Phys, 78(4): 1253-60. [Abstract] [Full-text]
  42. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.
    Int J Radiat Oncol Biol Phys, 78(4): 1086-94. [Abstract] [Full-text]
  43. Survivin is a potential mediator of prostate cancer metastasis.
    Int J Radiat Oncol Biol Phys, 78(4): 1095-103. [Abstract] [Full-text]
  44. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
    Int J Radiat Oncol Biol Phys, 78(4): 1081-5. [Abstract] [Full-text]
  45. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
    Int J Radiat Oncol Biol Phys, 78(4): 1210-8. [Abstract] [Full-text]
  46. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1104-10. [Abstract] [Full-text]
  47. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation.
    Exp Cell Res, 316(19): 3207-26. [Abstract] [Full-text]
  48. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.
    Int J Radiat Oncol Biol Phys, 78(4): 1253-60. [Abstract] [Full-text]
  49. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.
    Int J Radiat Oncol Biol Phys, 78(4): 1086-94. [Abstract] [Full-text]
  50. Survivin is a potential mediator of prostate cancer metastasis.
    Int J Radiat Oncol Biol Phys, 78(4): 1095-103. [Abstract] [Full-text]
  51. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
    Int J Radiat Oncol Biol Phys, 78(4): 1081-5. [Abstract] [Full-text]
  52. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
    Jpn J Clin Oncol, 40(11): 1092-8. [Abstract] [Full-text]
  53. Contrast-enhanced ultrasonography of the prostate with Sonazoid.
    Jpn J Clin Oncol, 40(11): 1099-104. [Abstract] [Full-text]
  54. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Prostate, 70(16): 1760-7. [Abstract] [Full-text]
  55. p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
    Prostate, 70(16): 1739-45. [Abstract] [Full-text]
  56. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Prostate, 70(16): 1788-98. [Abstract] [Full-text]
  57. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.
    Prostate, 70(16): 1799-808. [Abstract] [Full-text]
  58. Expression of cancer/testis antigens in prostate cancer is associated with disease progression.
    Prostate, 70(16): 1778-87. [Abstract] [Full-text]
  59. Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression.
    Prostate, 70(16): 1768-77. [Abstract] [Full-text]
  60. Gene expression correlation analysis predicts involvement of high- and low-confidence risk genes in different stages of prostate carcinogenesis.
    Prostate, 70(16): 1746-59. [Abstract] [Full-text]
  61. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
    Prostate, 70(16): 1729-38. [Abstract] [Full-text]
  62. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Prostate, 70(16): 1760-7. [Abstract] [Full-text]
  63. p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
    Prostate, 70(16): 1739-45. [Abstract] [Full-text]
  64. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Prostate, 70(16): 1788-98. [Abstract] [Full-text]
  65. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.
    Prostate, 70(16): 1799-808. [Abstract] [Full-text]
  66. Expression of cancer/testis antigens in prostate cancer is associated with disease progression.
    Prostate, 70(16): 1778-87. [Abstract] [Full-text]
  67. Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression.
    Prostate, 70(16): 1768-77. [Abstract] [Full-text]
  68. Gene expression correlation analysis predicts involvement of high- and low-confidence risk genes in different stages of prostate carcinogenesis.
    Prostate, 70(16): 1746-59. [Abstract] [Full-text]
  69. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
    Prostate, 70(16): 1729-38. [Abstract] [Full-text]
  70. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Prostate, 70(16): 1760-7. [Abstract] [Full-text]
  71. p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
    Prostate, 70(16): 1739-45. [Abstract] [Full-text]
  72. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Prostate, 70(16): 1788-98. [Abstract] [Full-text]
  73. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.
    Prostate, 70(16): 1799-808. [Abstract] [Full-text]
  74. Expression of cancer/testis antigens in prostate cancer is associated with disease progression.
    Prostate, 70(16): 1778-87. [Abstract] [Full-text]
  75. Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression.
    Prostate, 70(16): 1768-77. [Abstract] [Full-text]
  76. Gene expression correlation analysis predicts involvement of high- and low-confidence risk genes in different stages of prostate carcinogenesis.
    Prostate, 70(16): 1746-59. [Abstract] [Full-text]
  77. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
    Prostate, 70(16): 1729-38. [Abstract] [Full-text]
  78. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study.
    Int J Cancer, 128(1): 185-91. [Abstract] [Full-text]
  79. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.
    Int J Cancer, 128(1): 206-15. [Abstract] [Full-text]
  80. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study.
    Int J Cancer, 128(1): 185-91. [Abstract] [Full-text]
  81. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.
    Int J Cancer, 128(1): 206-15. [Abstract] [Full-text]
  82. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study.
    Int J Cancer, 128(1): 185-91. [Abstract] [Full-text]
  83. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.
    Int J Cancer, 128(1): 206-15. [Abstract] [Full-text]
  84. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.
    J Clin Oncol, 28(31): 4687-96. [Abstract] [Full-text]
  85. Hexane-ethanol extract of Glycyrrhiza uralensis containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells.
    Br J Nutr, 104(9): 1272-82. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience